01764nas a2200349   4500000000100000008004100001260001700042653001500059653001000074653002600084653002400110653001100134653001600145653001100161653001200172653002400184653000900208653001600217653002500233653002000258100001400278700001500292700001800307700001500325700001800340245011300358300001100471490000700482050003200489520087900521022001401400       2001                            d  c2001 Jul-Sep10aAdolescent10aAdult10aAntibodies, Bacterial10aAntigens, Bacterial10aFemale10aGlycolipids10aHumans10aleprosy10aLipopolysaccharides10aMale10aMiddle Aged10aMycobacterium leprae10aSerologic Tests1 aJayapal V1 aSelvibai G1 aMahalakshmi K1 aRegunath K1 aSubramanian S00aComparative study of anti-PGL-1, anti-35 kDa and anti-lipoarabinomannan assays for serodiagnosis of leprosy.  a229-370 v73  aInfolep Library - available3 a<p>Three antibody assays (anti-PGL-1, anti-35 kDa and anti-LAM) were used to determine the levels of antibodies in the sera of untreated leprosy patients. All the three assays showed higher levels of antibodies in BL/LL patients as compared to I and TT/BT patients, as well as healthy controls. BL/LL patients showed positivity of 100%, 84.2% and 78.9% by anti-PGL-1, anti-35 kDa and anti-LAM assays respectively. All the three assays were negative for leprosy in healthy controls. Anti-PGL-1 assay was positive in 20% of TT/BT patients and 17.9% of I patients. Anti-35 kDa assay was negative in all the TT/BT patients and positive in 7.14% of I patients. Anti-LAM assay was positive in 13.3% of TT/BT patients and in 10.7% of I patients. Hence, while these assays are valuable in diagnosing BL/LL patients, their usefulness in diagnosing I, BT or TT leprosy is limited.</p>  a0254-9395